Perforin-1

Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting

Retrieved on: 
Friday, April 5, 2024
HLE, Abstract, PDT, TME, CD8, Perforin-1, Tumor microenvironment, Cancer, AACR, Phenotype, Neoplasm, Therapy, Section 4, Granzyme, NK, Poster, Vaccine

WATERTOWN, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally-activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, is presenting preclinical data on development candidates WTX-518 and WTX-712 in posters at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego, California.

Key Points: 
  • “We are excited to share that both WTX-518 and WTX-712 demonstrate powerful immunotherapeutic effects in preclinical models,” said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf.
  • “WTX-518 exhibits remarkable tumor-selective activation, resistance to IL-18BP and robust immune activation, overcoming key hurdles in the use of this promising cytokine in cancer therapy.
  • WTX-712 acts through a unique mechanism that robustly activates tumor-specific T lymphocytes with an expanded therapeutic window through its selective release of wild-type IL-21 in the TME.
  • Werewolf plans to develop WTX-518 and WTX-712 as potential immunotherapies in refractory and/or immunologically unresponsive tumors.

AIM ImmunoTech Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen® for the Treatment of Advanced Recurrent Ovarian Cancer

Retrieved on: 
Wednesday, November 8, 2023
MSD, Society for Immunotherapy of Cancer, Plasma, AIM, NYSE, Ovarian cancer, Biomarker, Therapy, Tumor necrosis factor, Viral, TNF, Pembrolizumab, DSM-IV codes, Cisplatin, PBMC, CXCL9, Research, CXCR3, University of Pittsburgh School of Medicine, Function (mathematics), SITC, Immunotherapy, CXCL11, Perforin-1, Cancer, Annual general meeting, University, Tumor microenvironment, CXCL10, Wilfrid Sellars, TME, IP, Patient, UPMC, Pharmaceutical industry, Merck

OCALA, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, today announced encouraging translational data from an ongoing Phase 2 clinical trial utilizing AIM’s drug Ampligen® in patients with platinum-sensitive advanced recurrent ovarian cancer.

Key Points: 
  • The data was also made available at the conference in a poster presentation .
  • Sequential sampling of the IP cavity showed an increase in cellularity immediately after treatment consistent with an “acute” pro-inflammatory reaction.
  • These data show a similar profile to previously published data from Roswell Park in Stage 4 triple negative breast cancer.
  • Additionally, we hope to announce topline interim survival results from UPMC in the near future.”
    For more information about the Phase 2 clinical trial of platinum-sensitive advanced recurrent ovarian cancer utilizing Ampligen®, visit clinicaltrials.gov and reference identifier: NCT03734692.

Asher Bio Presents Promising New Preclinical Data for Cis-targeted Cancer Immunotherapy AB821 at SITC Annual Meeting

Retrieved on: 
Tuesday, October 31, 2023
Oncology, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, TILS, Neoplasm, Survival, IND, CD8, Clinical trial, Poster, SITC, Granzyme, Immunotherapy, Perforin-1, Annual general meeting, Infection, Society, Autoimmunity, Patient, Toxic epidermal necrolysis, Pharmaceutical industry, Vaccine, Palladium, Cancer

Asher Biotherapeutics , a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced new preclinical data for AB821, its CD8-targeted interleukin-21 (IL-21) immunotherapy.

Key Points: 
  • Asher Biotherapeutics , a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced new preclinical data for AB821, its CD8-targeted interleukin-21 (IL-21) immunotherapy.
  • The data will be presented at the Society for Immunotherapy in Cancer (SITC) 38th Annual Meeting, being held in San Diego, CA on November 1-5, 2023.
  • “We are pleased to share new preclinical data for AB821 at SITC, further illustrating the potential of our highly differentiated cis-targeted immunotherapies for the treatment of cancer,” said Andy Yeung, Ph.D., Chief Technology Officer and Co-founder of Asher Bio.
  • “IL-21 has historically demonstrated promising antitumor activity, but its clinical use has been limited due to toxicities and pleiotropic effects.

Corvus Pharmaceuticals Presents New CPI-818 Interim Data at the International Conference on Malignant Lymphoma

Retrieved on: 
Thursday, June 15, 2023
Antigen, CT, TCL, PRS, Perforin-1, ALC, Neoplasm, ICML, Infection, ITK, Lymphoma, Clinical trial, T-cell lymphoma, Research, RNA, Publication, Immunotherapy, Granzyme, CD8, International Conference of Marxist–Leninist Parties and Organizations (International Newsletter), B-cell lymphoma, Patient, Blood, CR, Biology, Poster, CD4, FDA, Tumor microenvironment, Conference, PR, Safety, Pharmaceutical industry, Vaccine, Medical imaging, Corvus

BURLINGAME, Calif., June 15, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced new data for CPI-818, the Company’s ITK inhibitor, demonstrating the potential to treat a variety of solid and hematological cancers based on a novel immunotherapy mechanism of action. The data includes updated interim results from the CPI-818 Phase 1/1b clinical trial that continues to demonstrate the potential of ITK inhibition and the absolute lymphocyte count (ALC) biomarker in T cell lymphoma (TCL). The data is being presented in a poster at the International Conference on Malignant Lymphoma (ICML) meeting, which is taking place June 13-17, 2023 in Lugano, Switzerland.

Key Points: 
  • The data includes updated interim results from the CPI-818 Phase 1/1b clinical trial that continues to demonstrate the potential of ITK inhibition and the absolute lymphocyte count (ALC) biomarker in T cell lymphoma (TCL).
  • The data is being presented in a poster at the International Conference on Malignant Lymphoma (ICML) meeting, which is taking place June 13-17, 2023 in Lugano, Switzerland.
  • “The preclinical and clinical data indicate a consistent and comprehensive rationale based on the biology and mechanism of immune enhancement resulting from selective ITK inhibition.
  • We see this in the interim tumor response data, which showed that a majority of the patients treated with the optimal dose of 200mg twice per day of CPI-818 experience tumor regression.

Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists

Retrieved on: 
Monday, May 15, 2023
Research, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, CITES, Therapy, DC, NK, Perforin-1, Journal of Immunology, T, Walter, Poster, Cytokine, Gene, Pharmaceutical industry, Vaccine, Extractive metallurgy

The meetings are taking place at the Walter E. Washington Convention center in Washington, DC, May 11 – 15.

Key Points: 
  • The meetings are taking place at the Walter E. Washington Convention center in Washington, DC, May 11 – 15.
  • “Equillium is developing EQ102 to selectively and synergistically block both IL-15 and IL-21 signaling, without affecting other gamma chain family members.
  • EQ102 is a multi-cytokine inhibitor that selectively blocks IL-15 and IL-21 signaling while preserving signaling of other γc family members.
  • Similarly, in pre-clinical studies, EQ102 has demonstrated the prevention of intestinal tissue damage in a humanized mouse model of gastrointestinal inflammation.

Orum Therapeutics Unveils New Program at AACR 2023, Highlighting Cbl-b Inhibitor-PD-1 Conjugate, and Presents New Data Supporting Clinical Development of Two GSPT1 Programs

Retrieved on: 
Tuesday, April 18, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, AACR, Perforin-1, PD, TP53, TGF, Neoplasm, ATF3, Cancer, Toxicity, SOC, Biomarker, Messenger, AML, Protein, Patient, Standard of care, Risk, T-cell surface glycoprotein CD3 epsilon chain, Growth, DDIT3, PD-1, FDA, Pembrolizumab, Therapy, GSPT1, Breast cancer, Vaccine, Palladium, Pharmaceutical industry, Regulatory T cell, CBL (gene)

The data were presented in three posters at the 2023 American Association for Cancer Research (AACR) Annual Meeting.

Key Points: 
  • The data were presented in three posters at the 2023 American Association for Cancer Research (AACR) Annual Meeting.
  • “We are also excited to unveil at AACR our new TPS² platform, which has the potential to achieve the full promise of Cbl-b inhibitors through T cell-specific delivery.
  • Orum identified the depletion of GSPT1 as a target-proximal pharmacodynamic biomarker in ORM-5029 treated in vitro and in vivo samples.
  • PD responses correlate with degree and duration of response in an in vivo model treated with ORM-5029.

Corvus Pharmaceuticals Presents New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid and Hematologic Cancers at the American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Monday, April 17, 2023
Antigen, T helper cell, AACR, Interferon gamma, TCL, Perforin-1, TNF, ALC, Neoplasm, Infection, ITK, Clinical trial, American Association for Cancer Research, NK, IL10, T-cell lymphoma, Cell, Publication, Immunotherapy, Colon, IL4, Hematological Cancer Research Investment and Education Act, Downregulation and upregulation, CD8, Animal, Patient, Enrollment, Melanoma, Immune system, Annual general meeting, IL17, Growth, Poster, CD4, IL9, Lymphocyte, Cytokine, FDA, ACL, B16, IL5, Tumor microenvironment, Safety, Vaccine, Pharmaceutical industry, Corvus

BURLINGAME, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced new data for CPI-818, the Company’s ITK inhibitor, demonstrating its potential to treat a variety of solid and hematological cancers based on a novel immunotherapy mechanism of action. The data will be presented today in a poster at the American Association for Cancer Research (AACR) Annual Meeting, which is taking place April 14-19, 2023 in Orlando, FL.

Key Points: 
  • The data will be presented today in a poster at the American Association for Cancer Research (AACR) Annual Meeting, which is taking place April 14-19, 2023 in Orlando, FL.
  • “CPI-818 inhibited tumor growth in five different tumor models including colon, renal and melanoma cancers, and in both T and B cell lymphomas.
  • These properties are a result of the myriad of functions that ITK plays in T cell biology.
  • The triplet combination led to complete tumor elimination in 19 of 20 animals with established CT26 colon cancer tumors.